<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02965404</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-VZV-1001</org_study_id>
    <nct_id>NCT02965404</nct_id>
  </id_info>
  <brief_title>A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children</brief_title>
  <official_title>A Blind, Randomized and Controlled Clinical Trial to Evaluate the Safety of Live Attenuated Varicella Vaccines for Healthy Adults, Adolescents and Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac (Dalian) Vaccine Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac (Dalian) Vaccine Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of a live attenuated varicella vaccine in&#xD;
      healthy adults, adolescents, and children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, blind, single-center, controlled phase I clinical trial. The&#xD;
      purpose of this study is to evaluate the safety of a live attenuated varicella vaccine&#xD;
      manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. The positive control is a&#xD;
      commercialized live attenuated varicella vaccine manufactured by Shanghai Institute of&#xD;
      Biological Products Co., Ltd. (SIBP), and the negative control is diluent of lyophilized&#xD;
      vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. All participants are&#xD;
      healthy, and will be randomly assigned into experimental group, positive control group, or&#xD;
      negative control group in the ratio 1:1:1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidences of adverse events (AEs) of each group</measure>
    <time_frame>30 days</time_frame>
    <description>AEs occurred within 30 days after injection will be collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidences of abnormal results of lab tests</measure>
    <time_frame>30 days</time_frame>
    <description>Cases of abnormal results of laboratory tests will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidences of serious adverse events (SAEs) of each group</measure>
    <time_frame>30 days</time_frame>
    <description>SAEs occurred within 30 days after injection will be collected.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;&#xD;
Intervention: investigational live attenuated varicella vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;&#xD;
Intervention: control live attenuated varicella vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative Control Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0;&#xD;
Intervention: diluent of lyophilized vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Investigational live attenuated varicella vaccine</intervention_name>
    <description>The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>control live attenuated varicella vaccine</intervention_name>
    <description>The control vaccine was manufactured by Shanghai Institute of Biological Products Co., Ltd. (SIBP)</description>
    <arm_group_label>Positive Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>diluent of lyophilized vaccine</intervention_name>
    <description>The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology</description>
    <arm_group_label>Negative Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteer between 1 - 49 years old;&#xD;
&#xD;
          -  Proven legal identity;&#xD;
&#xD;
          -  Guardian(s) of the volunteer and/or volunteers themselves should be capable of&#xD;
             understanding the written consent form, and such form should be signed before the&#xD;
             infant being included into this study;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior vaccination with varicella vaccine or with history of varicella zoster virus&#xD;
             (VZV) infection;&#xD;
&#xD;
          -  Axillaty temperature &gt; 37.0 Â°C;&#xD;
&#xD;
          -  Breast feeding, pregnant, or expected to conceive during the period of this trial;&#xD;
&#xD;
          -  History of allergy to any vaccine or vaccine ingredient, or serious adverse&#xD;
             reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic&#xD;
             edema, abdominal pain, etc;&#xD;
&#xD;
          -  History of epilepsy, seizures or convulsions, or a family history of mental illness;&#xD;
&#xD;
          -  Autoimmune disease or immunodeficiency;&#xD;
&#xD;
          -  Severe malnutrition, congenital malformation, developmental disorders, or serious&#xD;
             chronic diseases;&#xD;
&#xD;
          -  Acute disease or acute stage of chronic disease within 7 days prior to study entry;&#xD;
&#xD;
          -  Receipt of any of the following products:&#xD;
&#xD;
               1. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;&#xD;
&#xD;
               2. Any live attenuated vaccine within 1 month prior to study entry;&#xD;
&#xD;
               3. Any blood product, immunosuppressant, hormone, or other investigational&#xD;
                  medicine(s) within 30 days prior to study entry;&#xD;
&#xD;
          -  Any significant abnormity of heart, lung, skin, or pharynx;&#xD;
&#xD;
          -  Any of the pre-immune test results of the following indexes of laboratory tests showed&#xD;
             clinically significant abnormity:&#xD;
&#xD;
               1. Blood routine examinations: hemoglobin (Hb), white blood cells (WBC) count;&#xD;
&#xD;
               2. Blood biochemistry detections: alanine transferase (ALT), total bilirubin, blood&#xD;
                  urea nitrogen (BUN), creatinine;&#xD;
&#xD;
               3. Urine routine tests: urine protein, urine glucose, urine erythrocyte&#xD;
&#xD;
          -  Any other factor that suggesting the volunteer is unsuitable for this study based on&#xD;
             the opinions of investigators;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengli Xia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xiangcheng County Center for Disease Control and Prevention</name>
      <address>
        <city>Xuchang</city>
        <state>Henan</state>
        <zip>461700</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 14, 2016</study_first_submitted>
  <study_first_submitted_qc>November 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>live attenuated varicella vaccine</keyword>
  <keyword>safety</keyword>
  <keyword>adult</keyword>
  <keyword>adolescent</keyword>
  <keyword>child</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

